Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Anti-flu drug on market by 1999

Jeremy Laurance
Monday 28 September 1998 23:02 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

AN ANTI-FLU drug that can knock out the influenza virus and stop the symptoms of fever and headache could be on the market next winter.

The drug, called zanamivir, has been tested on more than 2,000 patients in Europe and the United States. Latest results, presented at a conference in San Diego, show it can cut the length of the illness by 2.5 days and reduces the severity of symptoms including cough, temperature and aches and pains.

GlaxoWellcome, which makes the drug, has applied for a licence in Europe and Canada following completion of the Phase III trials. Professor Chris Silagy, of Flinders Medical Centre in South Australia, one of the trialists, said: "Zanamivir ... stops influenza dead in its tracks."

If it proves acceptable to doctors and patients, the potential market for the drug could be worth billions. However, it is only effective against genuine flu, and not against coughs, colds or other flu-like illnesses.

Once licensed, it is likely to be made available on prescription only after the GP has conducted a test to confirm the presence of flu. This means that patients will have to attend their local surgery for the test immediately symptoms appear. Any delay will reduce its efficacy.

Patients will take the drug by inhaling it directly into their lungs, the same route that the flu virus takes when passing from person to person. A rival drug, made by Hoffman La Roche, which is at a similar stage of development, will be offered in pill form.

The drugs are the first of a new class called neuraminidase inhibitors, which do not stop infection but prevent the virus spreading within the body. The drugs work by blocking the action of neuraminidase, an enzyme "spike" on the surface of the flu virus which enables it to migrate through mucus in the lungs and spread among cells. Timing is critical. If given too late, the drugs have little effect.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in